Stockhub

Arrowhead Pharmaceuticals, Inc.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

15 August 2022

11 August 2022

2 August 2022

  • curprev 20:5520:55, 2 August 2022‎ Chris talk contribs‎ 1,938 bytes +1,938‎ Created page with "Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/Arrowhead_Pharmaceuticals,_Inc.’